Krishna Moturi, MD
Main:
(520) 694-2873
Fax: (520) 694-0255
Fax: (520) 694-0255
3838 North Campbell Avenue, Building 1, Tucson, Arizona, 85719
About us
As an oncologist, I am committed to providing compassionate, patient-centered care that honors each person’s unique journey. I believe in open communication and strive to create a supportive environment where my patients feel heard and understood. I would want to work collaboratively to develop personalized treatment plans that align with their individual needs, preferences, and goals.
I am dedicated to staying current on the latest medical advancements in order to provide my patients with the highest quality care.
Find Support at Banner Health.
| Languages | Telugu, Hindi, English |
| Tags | adjuvant chemotherapy, prolonged partial thromboplastin time, prolonged prothrombin time, plasmablastic lymphoma, neutrophilia, monoclonal b-cell lymphocytosis, macrocytosis, follicular t-cell lymphoma, elevated hemoglobin, b cell lymphoproliferative disorder, elevated transferrin saturation, elevated ferritin, high iron, autoimmune (aa) amyloidosis, light chain (al) amyloidosis, solitary plasmacytoma, metastatic blood cancers, human t-cell lymphotropic virus type 1, human t-cell lymphotropic virus type 2, thrombotic microangiopathy, paraprotein associated cryoglobulinemia, monoclonal gammopathy of renal significance, abnormal protein, blood cancer chemotherapy, iron infusion therapy, blood transfusion therapy, bone marrow aspiration, relapsed non hodgkin lymphoma, relapsed hodgkin lymphoma, lymphoproliferative disorder, alk negative anaplastic large cell lymphoma, smoldering multiple myeloma, extranodal nk t cell lymphoma, primary effusion lymphoma, primary splenic lymphoma, nodular lymphocyte predominant hodgkin lymphoma, disseminated intravascular coagulation, hiv lymphoma, coagulation disorders, bone marrow failure syndromes, autoimmune hemolytic anemia, hodgkin lymphoma, de-escalation treatment, neoadjuvant treatment, neurotrophic tyrosine receptor kinase gene fusion, complement mediated hemolytic uremic syndrome, chemotherapy toxicity, decreased hemoglobin, iron replacement, iron level, iron binding capacity, ferritin, cardiolipin antibody assay, hydroxyurea therapy, hypersplenism, acquired factor inhibitor, plasmacytoma, monoclonal paraproteinemia, marginal zone lymphoma, mantle zone lymphoma, large granular lymphocytic leukemia, hematologic malignancies, bone marrow biopsy, anaplastic large cell lymphoma, adult t cell lymphoma, thrombotic thrombocytopenic purpura, sezary syndrome, multiple myeloma, lupus anticoagulant, light chain disorders, hypercoagulable state, hairy cell leukemia, graft versus host disease, factor eight disorder, deep vein thrombosis, deep thrombophlebitis, cutaneous lymphoma, cutaneous b cell lymphoma, cns lymphoma, chronic lymphocytic leukemia, catastrophic antiphospholipid syndrome (caps), burkitt lymphoma, platelet disorder, blood clotting disorder, blood clot, antiphospholipid syndrome, anticoagulation, castleman's disease, poems syndrome, anemia of chronic disease, hemolytic anemia, monoclonal gammopathy of undetermined significance, plasma cell dyscrasia, lymphoma genomics, heparin induced thrombocytopenia, hemolytic uremic syndrome, hemochromatosis, b12 deficiency anemia, primary systemic amyloidosis, amyloidosis |
| Video | https://www.youtube.com/watch?v=YKy4r5S8h_s |